title: Hepatitis C therapy with long term remission after renal transplantation.
abstract: Hepatitis C virus infection (HCV) is common in patients with end-stage renal disease (ESRD) and long observation periods have shown the detrimental effect of HCV infection on patient and graft survival after renal transplantation. At present, interferon is the most important agent for the treatment of hepatitis C in ESRD; however, limited information exists concerning the long-term response of patients who undergo renal transplantation after successful antiviral therapy. We describe the evolution of HCV infection in a dialysis patient with hepatitis C who was successfully treated with interferon alpha and then underwent renal transplantation. He received aggressive immunosuppression during the induction phase and for allograft rejection; however, regular screening showed complete absence of biochemical and virological relapse of HCV over a 6-year post-transplantation period. We conclude that interferon can offer excellent response in selected dialysis patients with hepatitis C. Alternative strategies with newer antiviral agents are currently under active investigation.
authors.affiliation: Multi Organ Transplant Program, Cedars-Sinai Medical Center, UCLA School of Medicine, Los Angeles, CA 90048, USA Bunnapradist@cshs.org
authors.forename: S
authors.initials: S
authors.lastname: Bunnapradist
authors.forename: F
authors.initials: F
authors.lastname: Fabrizi
authors.forename: J
authors.initials: J
authors.lastname: Vierling
authors.forename: R
authors.initials: R
authors.lastname: Martin
authors.forename: A
authors.initials: A
authors.lastname: Moudgil
authors.forename: E
authors.initials: E
authors.lastname: Kamil
authors.forename: S
authors.initials: S
authors.lastname: Jordan
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D006084:Graft Rejection; D016174:Hepacivirus / Q000235:genetics / Q000302:isolation & purification*; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy*; D016030:Kidney Transplantation; D008297:Male; D010530:Peritoneal Dialysis; D016133:Polymerase Chain Reaction; D012074:Remission Induction
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha